Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03301038 · ClinicalTrials.gov registry record · Phase 2
Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria
A Phase 2 study of Genetic Disease and Hypercalciuria, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT03301038 is a Phase 2 study of Genetic Disease and Hypercalciuria that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 60 participants, below the 2,559-participant average among 30 other Genetic Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03301038, a Phase 2 study of Genetic Disease and Hypercalciuria, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and/or hypercalciuria in participants with at least one inactivating mutation of the CYP24A1 gene. Eligible subjects will receive rifampin for a total of 16 weeks during this study.
Conditions Studied
Interventions
- DRUG Rifampin
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-07-25 |
| Est. Completion | 2030-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03301038
The ClinicalTrials.gov registry entry for NCT03301038 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,559-participant average among 30 other Genetic Disease trials with a reported enrollment target (98% lower). The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Genetic Disease appearing as the primary indexed condition, and to 1 intervention - of which Rifampin is the first listed.
NCT03301038 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03301038 about?
NCT03301038 is a clinical study titled "Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria". This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and/or hypercalciuria in participants with at least one inactivating mutation of the CYP24A1 gene. Eligible subjects will receive rifampin for a total of 16 weeks during this study.
What is the current status of trial NCT03301038?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2018-07-25. Estimated completion is 2030-12.
What conditions does trial NCT03301038 study?
This clinical trial studies the following conditions: Genetic Disease, Hypercalciuria, Idiopathic Infantile Hypercalcaemia - Severe Form, Hypercalcemia, Idiopathic, of Infancy, Hypercalciuric Hypercalcemia.
What interventions are being tested in trial NCT03301038?
The interventions under investigation include: Rifampin (DRUG).
Who is sponsoring clinical trial NCT03301038?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03301038 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Adaptive Clinical Trial of BeginNGS Newborn Screening for Hundreds of Genetic Diseases by Genome Sequencing
RECRUITING · NA
-
Delineating the Molecular Spectrum and the Clinical, Imaging and Neuronal Phenotype of Chopra-Amiel-Gordon Syndrome
RECRUITING
-
Rett Syndrome Registry
RECRUITING
-
Natural History Study of Patients with HPDL Mutations
RECRUITING
-
Diagnostic Odyssey: Whole Genome Sequencing (WGS)
RECRUITING
-
Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.